Back to Search
Start Over
Integrating novel agents into multiple myeloma treatment - current status in Switzerland and treatment recommendations
- Source :
- Swiss Medical Weekly, vol. 140, pp. w13054, Schweizerische medizinische Wochenschrift, Vol. 140 (2010) P. w13054
- Publication Year :
- 2010
-
Abstract
- The treatment of multiple myeloma has undergone significant changes in the recent past. The arrival of novel agents, especially thalidomide, bortezomib and lenalidomide, has expanded treatment options and patient outcomes are improving significantly. This article summarises the discussions of an expert meeting which was held to debate current treatment practices for multiple myeloma in Switzerland concerning the role of the novel agents and to provide recommendations for their use in different treatment stages based on currently available clinical data. Novel agent combinations for the treatment of newly diagnosed, as well as relapsed multiple myeloma are examined. In addition, the role of novel agents in patients with cytogenetic abnormalities and renal impairment, as well as the management of the most frequent side effects of the novel agents are discussed. The aim of this article is to assist in treatment decisions in daily clinical practice to achieve the best possible outcome for patients with multiple myeloma.
- Subjects :
- ddc:616
Plasma Cells/drug effects/pathology
Dose-Response Relationship, Drug
Biopsy, Needle
Boronic Acids/adverse effects/therapeutic use
ddc:500.2
Antineoplastic Agents/adverse effects/*therapeutic use
Evidence-Based Medicine
Middle Aged
Combined Modality Therapy
Drug Administration Schedule
Multiple Myeloma/diagnosis/*drug therapy/pathology
Bone Marrow/drug effects/pathology
Pyrazines/adverse effects/therapeutic use
Drug Resistance, Neoplasm
Retreatment
Humans
Thalidomide/adverse effects/analogs & derivatives/therapeutic use
Neoplasm Recurrence, Local/drug therapy/pathology
Aged
Antineoplastic Agents/adverse effects
Antineoplastic Agents/therapeutic use
Bone Marrow/drug effects
Bone Marrow/pathology
Bone Marrow Transplantation
Boronic Acids/adverse effects
Boronic Acids/therapeutic use
Multiple Myeloma/diagnosis
Multiple Myeloma/drug therapy
Neoplasm Recurrence, Local/drug therapy
Neoplasm Recurrence, Local/pathology
Plasma Cells/drug effects
Plasma Cells/pathology
Pyrazines/adverse effects
Pyrazines/therapeutic use
Switzerland%22">Type="Geographic">Switzerland
Thalidomide/adverse effects
Thalidomide/analogs & derivatives
Switzerland
Subjects
Details
- Language :
- English
- ISSN :
- 00367672
- Database :
- OpenAIRE
- Journal :
- Swiss Medical Weekly, vol. 140, pp. w13054, Schweizerische medizinische Wochenschrift, Vol. 140 (2010) P. w13054
- Accession number :
- edsair.dedup.wf.001..f630e5a07ef469b041755bd84db8ab07